Letter of submission (correcteed version)
Dear Sirs,
We would like to submit the attached manuscript entitled
ENA-78 expression correlates with early stage onset of colorectal carcinoma
by
Claudia Rubie1*,Vilma Oliveira Frick1, Mathias Wagner2, Jochen Schuld1, Stefan
Graeber3, Rainer M. Bohle2, and Martin K. Schilling1
1Dept.
of General -, Visceral-, Vascular - and Paediatric Surgery, University of the
Saarland, 66421 Homburg/Saar, Germany
2Institute
of Pathology, University of the Saarland, 66421 Homburg/Saar, Germany
3Institute
of Medical Biometrics, Epidemiology, and Medical Informatics (IMBEI)
University of the Saarland, 66421 Homburg/Saar, Germany
for publication in BMC Molecular Cancer.
Subject:
In our study, we outlined a prominent expression profile for CXC chemokines
GROalpha and ENA-78 with respect to CRC pathology. ENA-78 exhibited a very
pronounced significant overexpression in the CRC and CRLM tissues with respect to
CRA tissues thus indicating a vast progressive increase in the transition from the
premalignant condition to the development of the malignant status. Along with a
much more pronounced up-regulation in the malignant tissues in comparison to
GROalpha and a significant clinicopathological correlation with early stage onset of
CRC, we regard ENA-78 as a most interesting candidate with respect to a potential
role in the progression from CRA to CRC and thus, in the initiation of CRC.
The content of the manuscript is original and it has not been published or accepted
for publication, either in whole or in part, in any form. No part of the manuscript is
currently under consideration for publication elsewhere.
Sincerely
Claudia Rubie
# Corresponding
author:
Claudia Rubie, PhD
Laboratory for Molecular Oncology
Dept. of General -, Visceral-, Vascular - and Paediatric Surgery
University of the Saarland 66421 Homburg/Saar, Germany,
Phone: +49-6841-16-23976, Fax: +49-6841-16-22497
e-mail: ca.labor@uniklinik-saarland.de